These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 29708261

  • 1. A cancer specific oxaliplatin-releasing Pt(iv)-prodrug.
    Reshetnikov V, Arkhypov A, Julakanti PR, Mokhir A.
    Dalton Trans; 2018 May 15; 47(19):6679-6682. PubMed ID: 29708261
    [Abstract] [Full Text] [Related]

  • 2. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z, Wang H, Li Y, Qin Y, Xu L, Bowers DJ, Gangoda M, Li X, Yang HB, Zheng YR.
    Chem Commun (Camb); 2018 Jan 18; 54(7):731-734. PubMed ID: 29303526
    [Abstract] [Full Text] [Related]

  • 3. Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.
    Savino S, Gandin V, Hoeschele JD, Marzano C, Natile G, Margiotta N.
    Dalton Trans; 2018 May 29; 47(21):7144-7158. PubMed ID: 29766157
    [Abstract] [Full Text] [Related]

  • 4. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y, Zhu Y, Cheng J, Shen J, Huang H, Liu M, Chen Z, Liu Y.
    Chem Commun (Camb); 2020 Nov 12; 56(90):14051-14054. PubMed ID: 33103676
    [Abstract] [Full Text] [Related]

  • 5. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 6. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 7. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X, Fang L, Zhao J, Gou S.
    Inorg Chem; 2018 May 07; 57(9):5019-5029. PubMed ID: 29667815
    [Abstract] [Full Text] [Related]

  • 8. A Dual Killing Strategy: Photocatalytic Generation of Singlet Oxygen with Concomitant PtIV Prodrug Activation.
    Norman DJ, Gambardella A, Mount AR, Murray AF, Bradley M.
    Angew Chem Int Ed Engl; 2019 Oct 01; 58(40):14189-14192. PubMed ID: 31397963
    [Abstract] [Full Text] [Related]

  • 9. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 10. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery.
    Zheng YR, Suntharalingam K, Johnstone TC, Yoo H, Lin W, Brooks JG, Lippard SJ.
    J Am Chem Soc; 2014 Jun 18; 136(24):8790-8. PubMed ID: 24902769
    [Abstract] [Full Text] [Related]

  • 11. Cis,cis,trans-[PtIVCl2(NH3)2(perillato)2], a dual-action prodrug with excellent cytotoxic and antimetastatic activity.
    Ravera M, Gabano E, Zanellato I, Rangone B, Perin E, Ferrari B, Bottone MG, Osella D.
    Dalton Trans; 2021 Mar 07; 50(9):3161-3177. PubMed ID: 33595015
    [Abstract] [Full Text] [Related]

  • 12. Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
    Xu Z, Hu W, Wang Z, Gou S.
    Eur J Med Chem; 2017 Dec 01; 141():211-220. PubMed ID: 29031068
    [Abstract] [Full Text] [Related]

  • 13. Novel hypoxia-targeting Pt(iv) prodrugs.
    Xu Z, Zhao J, Gou S, Xu G.
    Chem Commun (Camb); 2017 Mar 28; 53(26):3749-3752. PubMed ID: 28303266
    [Abstract] [Full Text] [Related]

  • 14. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 15. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 05; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 16. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D.
    J Med Chem; 2021 Aug 12; 64(15):11364-11378. PubMed ID: 34342437
    [Abstract] [Full Text] [Related]

  • 17. Biotinylated photoactive Pt(iv) anticancer complexes.
    Shi H, Imberti C, Huang H, Hands-Portman I, Sadler PJ.
    Chem Commun (Camb); 2020 Feb 21; 56(15):2320-2323. PubMed ID: 31990000
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. ctc-[Pt(NH3)2(cinnamate)(valproate)Cl2] is a highly potent and low-toxic triple action anticancer prodrug.
    Li Y, Shi S, Zhang S, Gan Z, Wang X, Zhao X, Zhu Y, Cao M, Wang X, Li W.
    Dalton Trans; 2021 Aug 28; 50(32):11180-11188. PubMed ID: 34338267
    [Abstract] [Full Text] [Related]

  • 20. Spatiotemporal Concurrent Liberation of Cytotoxins from Dual-Prodrug Nanomedicine for Synergistic Antitumor Therapy.
    Zhang L, Qian M, Cui H, Zeng S, Wang J, Chen Q.
    ACS Appl Mater Interfaces; 2021 Feb 10; 13(5):6053-6068. PubMed ID: 33525873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.